Vasopressors or Fluids in Early Septic Shock
New England Journal of Medicine · 08.10.2026 · 395 (14) · 1387-1398
DOI: 10.1056/nejmoa2516225 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 08.10.2026. Verfasst von ARISE FLUIDS Investigators, the ANZICS Clinical Trials Group, and the ACEM Clinical Trials Network und 19 weiteren Autor:innen. Beteiligte Einrichtung: Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Austra…. Hauptthemen laut MEDLINE: Fluid Therapy, Resuscitation, Shock, Septic, Vasoconstrictor Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: National Health and Medical Research Council, Health Research Council of New Zealand, Australian National Health and Medical Research Council.
Themen: Sepsis
Abstract (Originalsprache)
BACKGROUND: The optimal approach to early resuscitation in septic shock is unknown. Equipoise exists between the use of larger volumes of intravenous fluids to restore perfusion and the use of early vasopressor therapy along with smaller volumes of fluids to minimize potential harm from excess fluid. METHODS: We randomly assigned adult patients who presented to the emergency department with septic shock to receive either fluids at restricted volumes and early vasopressor therapy (vasopressor group) or higher volumes of fluids and later vasopressor therapy (fluids group) for at least 6 hours and up to 24 hours. The primary outcome was days alive and out of the hospital from randomization to day 90. RESULTS: A total of 1000 patients underwent randomization, with 499 assigned to the vasopressor group and 501 to the fluids group. Informed consent was not obtained for 37 patients, which left 963 patients in the intention-to-treat population (481 in the vasopressor group and 482 in the fluids group). Three patients in the fluids group were lost to follow-up for the primary outcome. In the first 24 hours after randomization, patients in the vasopressor group received less intravenous fluid than those in the fluids group (median difference, -1108 ml; 95% confidence interval [CI], -1395 to -850). The percentage of patients who received vasopressors was higher by 18.9 percentage points (95% CI, 13.3 to 24.5) in the vasopressor group. The median number of days alive and out of the hospital at day 90 was 76 (interquartile range, 55 to 83) in the vasopressor group and 76 (interquartile range, 55 to 82) in the fluids group (difference, 0.0 days; 95% CI, -2.7 to 2.7; P = 1.00). Adverse events occurred in similar percentages of patients in the two groups, except for pulmonary edema (0.6% in the vasopressor group vs. 5.0% in the fluids group; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
- Adelaide University, School of Medicine, Adelaide, SA, Australia.
- Department of Intensive Care Medicine, Queen Elizabeth Hospital, Woodville South, SA, Australia.
- Centre for Clinical Research in Emergency Medicine, Harry Perkins Institute of Medical Research, Perth, WA, Australia.
- Medical School, University of Western Australia, Crawley, Australia.
- Intensive Care Services, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
ORCID-Profile: Sandra L Peake, John F Fraser, Alisa M Higgins, Paul J Young
Förderung
- National Health and Medical Research Council
- Health Research Council of New Zealand
- Australian National Health and Medical Research Council
Zitieren
APA
ARISE FLUIDS Investigators, the ANZICS Clinical Trials Group, and the ACEM Clinical Trials Network, Peake, S. L., Macdonald, S. P. J., Howe, B. D., Milford, E., Jones, P., Arendts, G., Bailey, M., Burcham, J., Delaney, A., Egerton-Warburton, D., Fatovich, D., Fraser, J. F., Higgins, A. M., Keijzers, G., Udy, A. A., Williams, P., Young, P. J., Bellomo, R., & The ARISE FLUIDS Investigators, the ANZICS Clinical Trials Group, and the ACEM Clinical Trials Network (2026). Vasopressors or Fluids in Early Septic Shock. New England Journal of Medicine, 395(14), 1387-1398. https://doi.org/10.1056/nejmoa2516225
Vancouver
ARISE FLUIDS Investigators, the ANZICS Clinical Trials Group, and the ACEM Clinical Trials Network, Peake SL, Macdonald SPJ, Howe BD, Milford E, Jones P, et al. Vasopressors or Fluids in Early Septic Shock. New England Journal of Medicine. 2026;395(14):1387-1398. doi:10.1056/nejmoa2516225
BibTeX
@article{ARISEFLUIDSInvestigatorstheANZICSClinicalTrialsGroupandtheACEMClinicalTrialsNetwork2026,
author = {ARISE FLUIDS Investigators, the ANZICS Clinical Trials Group, and the ACEM Clinical Trials Network, ARISE FLUIDS Investigators, the ANZICS Clinical Trials Group, and the ACEM Clinical Trials Network and Peake, Sandra L and Macdonald, Stephen P J and Howe, Belinda D and Milford, Elissa and Jones, Peter and Arendts, Glenn and Bailey, Michael and Burcham, Jonathon and Delaney, Anthony and Egerton-Warburton, Diana and Fatovich, Daniel and Fraser, John F and Higgins, Alisa M and Keijzers, Gerben and Udy, Andrew A and Williams, Patricia and Young, Paul J and Bellomo, Rinaldo and The ARISE FLUIDS Investigators, the ANZICS Clinical Trials Group, and the ACEM Clinical Trials Network, The ARISE FLUIDS Investigators, the ANZICS Clinical Trials Group, and the ACEM Clinical Trials Network},
title = {Vasopressors or Fluids in Early Septic Shock},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {14},
pages = {1387--1398},
doi = {10.1056/nejmoa2516225}
}
EUVIMED